Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
BP Keenan, L Fong, RK Kelley - Journal for immunotherapy of cancer, 2019 - Springer
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …
Inflammatory mechanisms of HCC development
MG Refolo, C Messa, V Guerra, BI Carr… - Cancers, 2020 - mdpi.com
HCC (hepatocellular carcinoma) is the second leading cause of cancer deaths worldwide,
with several etiologic causes, mostly inflammation-associated. Different inflammatory …
with several etiologic causes, mostly inflammation-associated. Different inflammatory …
[HTML][HTML] A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma
The role of TGF-β-induced epithelial-mesenchymal transition (EMT) in cancer cell
dissemination is well established, but the involvement of lncRNAs in TGF-β signaling is still …
dissemination is well established, but the involvement of lncRNAs in TGF-β signaling is still …
[HTML][HTML] TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling
W Su, W Gao, R Zhang, Q Wang, L Li, Q Bu, Z Xu, Z Liu… - JHEP reports, 2023 - Elsevier
Background & Aims Oxidative stress-mediated ferroptosis and macrophage-related
inflammation play an important role in various liver diseases. Here, we explored if and how …
inflammation play an important role in various liver diseases. Here, we explored if and how …
[PDF][PDF] Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice
Transforming growth factor beta (TGF‐β) signaling activates Smad‐and TGF‐β‐activated
kinase 1 (TAK1)‐dependent signaling to regulate cell survival, proliferation, fibrosis, and …
kinase 1 (TAK1)‐dependent signaling to regulate cell survival, proliferation, fibrosis, and …
[PDF][PDF] Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (ie,
nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer …
nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer …
Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling
D Xiang, J Zou, X Zhu, X Chen, J Luo, L Kong, H Zhang - Phytomedicine, 2020 - Elsevier
Background Hepatic fibrosis is considered integral to the progression of chronic liver
diseases, as it leads to the development of cirrhosis and hepatocellular carcinoma. The …
diseases, as it leads to the development of cirrhosis and hepatocellular carcinoma. The …
Schisantherin A ameliorates liver fibrosis through TGF-β1mediated activation of TAK1/MAPK and NF-κB pathways in vitro and in vivo
H Wang, J Che, K Cui, W Zhuang, H Li, J Sun, J Chen… - Phytomedicine, 2021 - Elsevier
Backgroud Schisandra chinensis, a traditional Chinese medicine for liver protection, can
significantly improve liver fibrosis. However, it is still unclear which active components in …
significantly improve liver fibrosis. However, it is still unclear which active components in …
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis
YX Ji, Z Huang, X Yang, X Wang, LP Zhao, PX Wang… - Nature medicine, 2018 - nature.com
Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to
advanced liver diseases. Lack of effective pharmacotherapies for NASH is largely …
advanced liver diseases. Lack of effective pharmacotherapies for NASH is largely …